The UK's health cost body National Institute for Health and Clinical Excellence, or NICE, in its revised draft guidance did not recommend Swiss pharmaceutical giant Novartis' multiple sclerosis pill Gilenya, as it believes the drug would not be cost effective for the National Health Service, or NHS, in comparison with other available treatments. NICE has not yet issued guidance for the NHS.
Gilenya, or fingolimod, is a daily capsule that could reduce relapses in some people who have a particular type of multiple sclerosis.
Even after a proposed discount from Novartis, NICE's independent appraisal committee is not convinced that offering the drug would be a cost effective option for the NHS, when compared with existing treatments such as beta interferons.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1309